2019 Agenda

October 2, 2019
  • 7:30 AM
    Registration and Breakfast
  • 8:15 AM
    Opening Comments from the Chair
    Kaitlyn Proulx
    Managing Director, PDCI, Market Access
    John-Paul Dowson
    Director, Reimbursement Strategy, PDCI
  • 8:30 AM
    Opening Keynote Address: Drug Pricing Reform in Canada
    Evaluate its Impact on your Market Access Strategy
    Douglas Clark
    Executive Director, PMPRB

    With the anticipated pricing reforms poised to become reality, it is time to assess what impact they will have on new product launches and pricing.  Elevate your understanding of how to position your product under the new guidelines.  Gain insight to help you:

    • Realistically assess your pricing options
    • Evaluate the potential ROI for Canadian product launches
    • Determine your forward strategy for the Canadian marketplace

    Successfully manage the impact of pricing reform on your company’s bottom line

  • 9:00 AM
    Panel Discussion: National Drug Agency
    Prepare Your Organization for the Impact that a New National Drug Agency Could Have on the Canadian Pharmaceutical Market
    Pamela Fralick
    President, Innovative Medicines Canada
    Dr. Luc Boileau
    President and CEO, INESSS

    Due to be launched by 2023, the new national drug agency recently announced by the federal government will totally transform the pharmaceutical market in Canada.  Gain insight into what this will mean for your organization.  Advance your preparedness strategy by learning:

    • What overall structure is being seriously considered and what functions it will include
    • Whether it will mean a more streamlined market access process
    • The potential impact on drug availability, pricing and on the overall industry

    Advance your understanding of the potential impact the new national drug agency could have on your organization.

  • 9:45 AM
    Panel Discussion: PLAs
    Position your Company to Succeed with Strategies for Negotiating Product Listing Agreements in an Uncertain Marketplace
    Kaitlyn Proulx
    Managing Director, PDCI, Market Access
    Helen Trifonopolis
    Head, Health Policy and Patient Access, Novartis Oncology, Novartis Pharmaceuticals Canada Inc.
    Imran Ali
    Senior Manager, pCPA
    John-Paul Dowson
    Director, Reimbursement Strategy, PDCI

    The move toward the establishment of a national drug agency will cause some disruption to the normal approval process while its final structure takes shape.  Get the insight you need to understand what changes may be on the horizon for new drug submissions.  Walk away with knowledge that will help you:

    • Understand the current pCPA submission process and how that may evolve
    • Gain insight into any changes in how provinces will now approach PLAs
    • Position your products for the best chance of success under the emerging new system

    Be on top of new developments for PLA submissions


  • 10:30 AM
    Networking Break
  • 11:00 AM
    Industry Expert: RWE
    Gain Insight into How Real World Evidence (RWE) is being Improved to Support Decision-making

    Having the clearest picture possible regarding how a broad cross-section of patients will react to new drugs is critical for government payers and patient groups.  Explore current innovation and the progress of Health Canada’s RWE project launched in 2018 to improve the value, efficacy and impact of medicines.  Take away strategies to help you:

    • Engage with stakeholders and gather data to improve efficacy
    • Understand how data will be shared among health care system partners
    • Gain clarity on the sources of data and how RWE will be used in the decision-making process

    Work with stakeholders to prove and improve the efficacy of your medicines.


    Senior Representative, IQVIA

  • 11:30 PM
    Expert Insight: Path to Market
    Analyze Emerging Trends in the Path to Market for Drug/Device Combinations and Position Your New Product for Success
    Louis Theriault
    VP Policy & Research, Innovative Medicines Canada

    New technology has enabled the development of drug/device and biologic combination products that target specific areas of the body and some which are genetically based.  While these innovative therapies are more effective, determining the applicable regulation and path to market can be challenging.  Gain insights to:

    • Help you determine the ‘Primary Mode of Action’ that will classify your product
    • Understand where drug/device regulations intersect and current progress of The Regulatory Review of Drugs and Devices (R2D2)
    • Assess how RWE will be gathered and applied to these products particularly those that require companion diagnostics

    Anticipate and adapt to changes underway in the approval of combination products.

  • 12:00 PM
  • 1:15 PM
    Panel Discussion:
    Be Prepared for Major Changes on Pricing and Market Access
    Joe Farago
    Executive Director, Private Payers & Investment, Innovative Medicines Canada

    There are many possible approaches that could be taken to establishing a national pharmacare program.  Understanding what direction is emerging from discussions among stakeholders as the most likely to taken once plans are actually underway, will be critical for your pricing and market access strategy.  Gain insights for your organization through discussion about:

    • What underlying principles should be prioritized in developing a national plan
    • Whether there will be greater collaboration between public and private payers to fill in the current gaps in coverage
    • What can be learned from Quebec’s universal model and whether Quebec will likely join

    Hear the latest discussions and prepare your organization for the new era in pharmacare.


  • 2:15 PM
    Panel Discussion: Pharmacoeconomics
    Adapt Your Company to Continuing Evolution of Pricing and Market Access for Private Payers
    John Herbert
    Director, Clinical, Research & New Solutions, Express Scripts (Canada)

    Along with the public sector, private payers have also increased their scrutiny of the effectiveness and value for money represented by the drugs they approve for their formularies.  Should a national pharmacare program be established, the use of pharmacoeconomics as an evaluative tool seems likely to increase, and provide greater harmonization between the standards of public and private payers for evaluating new drug submissions.  Gain insight that will help you craft your market access strategy by learning:

    • Whether the establishment of a national pharmacare program will foster greater collaboration between public and private payers to achieve the goal of universal coverage for Canadians
    • What role pharmacoeconomics will play going forward for private payers
    • What pharma companies can do now to optimize the ROI of their submissions to private payers

    Understand how private payer market access is changing and how you can adapt.


  • 2:45 PM
    Networking Break
  • 3:15 PM
    Panel Discussion: Employer Perspective
    What Employers Want and How they are Responding to Higher Drug Costs in Benefit Plans
    Joan Weir
    Director, Health and Disability Policy, Canadian Life and Health Insurance Association (CLHIA)
    Barbara Martinez
    Practice Leader, Benefits Solutions, Great-West Life

    In the face of constantly rising drug costs, employers are having to implement strategies to ensure their plans are sustainable.  Learn what measures they are adopting to address skyrocketing drug prices.  Walk away with actionable insights to inform your forward strategy by:

    • Understanding the risks presented by biologics and the resulting move toward price caps and stop-loss insurance
    • Discovering the increasing role biosimilars are expected to play in keeping costs down
    • Gaining awareness into the new relationships that are emerging with pharmacists to monitor drug plan performance

    Ensure your market access plan has the best shot at success by understanding what employers need.

  • 4:00 PM
    Keynote Address: The Report of the Standing Committee on Health
    Anticipate Change to Market Access and Pricing Models in Canada: The Forward Impact of The Report of the Standing Committee on Health

    The Report of the Standing Committee on Health titled “Towards Open Science: Promoting Innovation in Pharmaceutical Research and Development and Access to Affordable Medications both in Canada and Abroad” included nine recommendations which, if adopted, would significantly alter drug development pricing and market access in Canada.  Inform your market access strategy with greater insight into changing industry dynamics.  Walk away with a roadmap to:

    • Position your company to navigate leading-edge developments for new models of drug discovery and reimbursement
    • Explore strategies for mutually beneficial collaboration
    • Determine whether open science models of drug development can be compatible with your company’s goals and objectives

    Anticipate change to industry dynamics that could significantly impact your market access and pricing strategies

  • 4:30 PM
    Panel Discussion: Increasing Opportunities for Market Access by
    Improving Incentives for Drug Development in Canada
    Max Morgan
    Head of Policy, Structural Genomics Consortium (SGC)

    Canada’s relatively small market has been viewed as an obstacle to attracting drug R&D.  That could change if a new approach were adopted that included incentives to conduct R&D in Canada.  Take back to your team insights to:

    • Understand the incentives other countries have established that have proven successful in attracting R&D
    • Discover whether there is value to offering incentives, whether they will encourage innovation, and if they will ultimately lead to lower drug costs
    • Determine if there are economic arguments to offer incentives if they have a broader positive impact beyond drug costs for public health systems

    Analyze what benefits could be gained by offering incentives to attract R&D to Canada.


  • 5:15 PM
    Conference Adjourns to Day Two
  • 5:15 PM - 6:15 PM
    Cocktail Reception
October 2, 2019
October 3, 2019
  • 7:45 AM
    Registration and Breakfast
  • 8:30 AM
    Opening Comments from the Chair
  • 8:45 AM
    Opening Keynote Address: U.S. Drug Pricing
    Stemming the Rising Tide of Drug Costs in the U.S.

    While other countries have adopted measures to reign in the skyrocketing prices of new therapies, the U.S. has resisted adopting this approach – until now.  The Trump administration has set lowering drug prices as a key goal and has put forward proposals to achieve this, which if successful, could have a significant impact both within and beyond the U.S.  Gain key insights into:

    • Progress being made to end rebates provided by pharmaceutical manufacturers to Pharmaceutical Benefit Managers (PBMs) in exchange for adding their products to formularies
    • The expected benefits should this initiative be successful and potential broader ramifications
    • What the ultimate outcome may be for the plan to adopt international pricing for certain drugs covered by Medicare

    Ensure your company is on top of emerging price developments in the U.S

  • 9:15 AM
    Expert Insight: CUSMA
    Understand the Impact that the CUSMA Agreement Will Likely Have on Pharmaceutical Market Access and Pricing to Advance Your Organization’s Strategy

    The new North American trade agreement extends data protection for biologics from 8 to 10 years.  While this provides greater opportunities for Brand manufacturers, it may create greater push-back from payers trying to keep their costs at sustainable levels.  Discover the probable outcome of this extended protection and fine-tune your strategy by learning:

    • What progress has been made toward ratification of the CUSMA
    • What economic impact the data protection extension could have on drug prices in Canada
    • Whether any new Canadian market developments are likely to change the upward price trajectory for new biologic medications given extended protection under CUSMA

    Prepare your company for additional data protection for biologics under USMCA.

  • 9:45 AM
    Case Study: SickKids Centre for Genetic Medicine
    The Transformative Impact Precision Medicine Can Have for Patients, Payers and the Path to Market

    Individualized medicine is proving to be an exciting emerging area that is already having a tremendously positive impact for patient diagnostics and treatment.  The Centre for Genetic Medicine at Sickkids is on the forefront of this radical shift in how we think about treating patients.  Gain valuable insight into:

    • What successes and challenges the Centre has encountered so far in achieving its objectives
    • Why collaboration has been key to the development of treatment pathways for patients
    • What wider impact the Centre’s success could have on the future of drug development

    Prepare your organization for the transformation precision medicine will bring.


  • 10:15 AM
    Networking Break
  • 10:45 AM
    Case Study: Tackling the Problem of Drug Development for Rare Diseases
  • 11:15 AM
    Panel Discussion: Rare Disease Drug Costs
    Reinvent the Path to Market by Transforming Drug Development for Rare Diseases
    Durhane Wong-Rieger
    President & CEO, CORD
    Dr. Larry Lynd
    Professor and Director, Collaboration for Outcomes Research and Evaluation (CORE)UBC

    Developing, delivering and funding treatment for patients with rare diseases has become the single biggest challenge for payers, patients and manufacturers.  With a growing consensus that a new drug development model is needed, the question becomes what form should it take?  Get the latest on how this question may be resolved.  Shape your strategy by hearing the latest views on:

    • What options could be pursued for the funding and development of ‘orphan’ drugs so they are more affordable for payers and patients
    • What new routes to commercialization for these medications may need to be forged
    • What types of partnerships will be key to successful development going forward


    Understand how the drug development model could fundamentally change for rare diseases.

  • 12:00 PM
  • 1:15 PM
    Expert Insight: ROI of Drugs
    Assessing the ROI of New Complex Therapies for Payers and Health System Budgets
    Dr. Larry Lynd
    Professor and Director, Collaboration for Outcomes Research and Evaluation (CORE)UBC

    The extremely high cost of some new medicines has been garnering a lot of attention lately.  However, there are economic benefits of these therapies reduce patient treatments.  Gain greater understanding of the ROI new medicines represent to incorporate into your analysis and decision-making.    Walk away with insight to:

    • Enhance your understanding of the overall value proposition innovative new therapies represent to formulary management
    • Improve the perceived ROI of your new products to public and private payers
    • Achieve a broader perspective in analysing the costs of new treatments

    Get the bigger picture of the return on investment of innovative medicines.

  • 1:45 PM
    Panel Discussion: Biosimilars Path to Market
    Improve your Market Access Strategy with Insights on the Evolving Path to Market for Biosimilars
    Chander Sehgal
    Associate Director, Innovation, Teva Canada
    Sang Mi Lee
    Senior Pharmacist, pCPA

    The growth of the biosimilar market has been sluggish due to a number of reasons that include regulatory requirements, production costs, patient preferences and a reluctance on the part of some physicians to prescribe them.  Yet as they represent significant cost savings, their adoption will only increase.  Heighten your awareness of the increased market impact and future direction for biosimilars.      Obtain useful insights to help you:

    • Determine how the Canadian regulatory process can be better aligned with that of the EU where they receive more favourable treatment
    • Assess the impact of gain greater take-up rates for biosimilars on public and private formularies
    • Include greater knowledge of biosimilar advancement in your market strategy

    Improve the path to market for biosimilars and achieve lower treatment costs.

  • 2:30 PM
    Networking Break
  • 3:00 PM
    Case Study – Patient Support Programs
    Building Patient Support Programs for Biosimilars

    A key feature of new life-saving biologic medicines is the patient support programs offered by Brands that patients rely on to ensure their treatment stays on track.  Offering similar patient support has represented a huge challenge for biosimilars that may now be overcome, finally enabling them to be adopted at a far higher rate.  Revise your biosimilar listing strategy with the latest news on this ground-breaking development by learning:

    • The progress that has been made over the last year since Biosimilars Canada Patient Support Program (PSP) platform was announced
    • What new opportunities this represents for cancer patients
    • The potential savings this development represents for payers

    Be on top of this game-changing development for biosimilars, patients and payers.


  • 3:30 PM
    Case Study: Blockchain
    Learn How Blockchain Technology Can be Used to Improve Clinical Trials and Ultimately Market Access

    When applied to clinical trials, blockchain technology has the potential to streamline their complexity and offer huge improvements to efficiency, data integrity, and transparency.  Gain insight into how blockchain could improve your market access process through higher quality clinical trials and documentation.  Advance your market access strategy by learning:

    • How blockchain can improve the accuracy of clinical trial records and bolster the data integrity of your submissions
    • What process efficiencies blockchain can deliver to reduce costs within your market access process
    • How more precise documentation improves interpretation clarity of trial results and patient safety

    Transform your market access strategy by incorporating blockchain technology into your clinical trials

  • 4:00 PM
    Expert Insight: Cannabis
    Clarifying the Path to Market for Cannabis-based Medicines

    The recent surge of serious interest in cannabis as an effective treatment for a variety of conditions including PTSD, has exposed some gaps in our current market access system.  However, as greater amounts of data and evidence are being gathered about its therapeutic value, greater interest and acceptance is being generated among payers.  Hone your medicinal cannabis strategy by:

    • Gaining insight into current reimbursement policies concerning medical cannabis for both public and private payers
    • Understanding when cannabis products are considered a drug or a natural health product and how a DIN or NHP can be obtained
    • Advancing your knowledge of current developments and the future evolution of this exciting new frontier for treatment

    Discover market access strategies for cannabis products in an evolving market.



  • 4:30 PM
    Conference Concludes
October 3, 2019
October 4, 2019
  • 9:00 AM - 12:00 PM
    Post-Conference Workshop: Product Listing Agreement
    Drive Successful pCPA Strategies and PLAs to Solidify your Market Access Strategies
    Colin Vicente
    Managing Director, Pivina

    The pan-Canadian Pharmaceutical Alliance (pCPA) administers the formal process for getting new drugs to the marketplace.  Source insights to manage and optimize your submission.  Tap into both public and private perspectives in this interactive workshop and walk away with knowledge to:


    1. Understand the pCPA process and submissions
    2. Prepare for pCPA in the planning stages of your products
    3. Use pricing models to assist your product’s positional during negotiations
    4. Gain an understanding of different types of Canadian PLAs
    5. Take advantage of potential opportunities in private sector PLAs


    Develop your successful pCPA strategy through this hands-on interactive workshop.

October 4, 2019

Download 2018 Brochure - Gain new ideas and practical strategies for implementation

  • This field is for validation purposes and should be left unchanged.